BeyondSpring (BYSI) Given a $52.00 Price Target at Maxim Group

BeyondSpring (NASDAQ:BYSI) has been assigned a $52.00 price target by research analysts at Maxim Group in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 59.95% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. HC Wainwright set a $60.00 target price on shares of BeyondSpring and gave the stock a “buy” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of BeyondSpring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th.

BeyondSpring (BYSI) traded down $1.30 on Thursday, reaching $32.51. 432 shares of the company’s stock traded hands, compared to its average volume of 5,475. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.01. equities research analysts predict that BeyondSpring will post -4.41 EPS for the current year.

A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new position in BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring makes up about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring as of its most recent SEC filing. Institutional investors own 1.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “BeyondSpring (BYSI) Given a $52.00 Price Target at Maxim Group” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with's FREE daily email newsletter.

Leave a Reply